Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

J. Reusch; M. W. Stewart; C. M. Perkins; D. T. Cirkel; J. Ye; C. R. Perry; R. R. Reinhardt; B. W. Bode

doi:10.1111/dom.12382

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Diabetes Obesity and Metabolism ◽

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Cited By ~ 1

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes Obesity and Metabolism ◽

10.1111/dom.13979 ◽

2020 ◽

Vol 22 (6) ◽

pp. 938-946 ◽

Cited By ~ 5

Author(s):

Juan Pablo Frias ◽

Michael A. Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients with Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism ◽

10.31031/gjem.2018.02.000543 ◽

2018 ◽

Vol 2 (4) ◽

Author(s):

Davis Townsend

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12898 ◽

2017 ◽

Vol 19 (6) ◽

pp. 874-882 ◽

Cited By ~ 28

Author(s):

Takashi Kadowaki ◽

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Kenichi Nishimura ◽

Genki Kaneko ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14231 ◽

2020 ◽

Author(s):

Wenying Yang ◽

Xiangjin Xu ◽

Tao Lei ◽

Jianhua Ma ◽

Ling Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Chinese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1359259 ◽

2017 ◽

Vol 18 (13) ◽

pp. 1291-1300 ◽

Cited By ~ 16

Author(s):

Takashi Kadowaki ◽

Kazuoki Kondo ◽

Noriyuki Sasaki ◽

Kyoko Miyayama ◽

Shoko Yokota ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Diabetes Care ◽

10.2337/dc11-1935 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1225-1231 ◽

Cited By ~ 154

Author(s):

V. A. Fonseca ◽

R. Alvarado-Ruiz ◽

D. Raccah ◽

G. Boka ◽

P. Miossec ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

SaO008THE EFFICACY AND SAFETY OF IMARIKIREN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MICROALBUMINURIA: A RANDOMIZED, MULTI CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy104.sao008 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i317-i318

Author(s):

Sadayoshi Ito ◽

Tomoya Kagawa ◽

Yuusuke Umeda ◽

Yuhei Sano ◽

Kohei Shimizu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text